可可-胡卜混合物急性摄入改变了与2型糖尿病患者胰岛素敏感性相关的miRNAs:一个随机对照的营养试验
Marisol Villalva1,2, Esther García-Díez2, María Del Carmen López de Las Hazas3
1Institute of Food Science Research (CIAL), Universidad Autónoma de Madrid, CEI UAM + CSIC, Madrid, Spain.
Food & function
|April 7, 2025
概括
可可-胡卜混合物 (CCB) 对2型糖尿病 (T2D) 患者显示出适度的益处,减少饥饿感和改变与胰岛素敏感性相关的外体miRNA. 需要进一步的长期研究来证实这些发现.
科学领域:
- 营养科学 营养科学
- 代谢健康 代谢健康
- 糖尿病研究 糖尿病研究
背景情况:
- 饭后代谢障碍在2型糖尿病 (T2D) 中很常见.
- 临床前研究表明,可可和胡卜可以改善代谢健康,但缺乏关于它们联合作用的临床数据.
- 这项研究调查了可可-胡卜混合物 (CCB) 对T2D和超重/肥胖患者的代谢参数的急性影响.
研究的目的:
- 评估可可-胡卜混合物 (CCB) 对患有2型糖尿病 (T2D) 和超重/肥胖的参与者的急性食后影响.
- 评估CCB对葡萄糖平衡,胰岛素敏感性,和炎症标志物的影响.
主要方法:
- 一个急性,随机,受控,交叉营养试验,涉及20名患有T2D和超重/肥胖的参与者.
- 进行了三种治疗:对照高热量早餐 (C),与CCB相同的早餐 (A),以及之前使用CCB后相同的早餐 (B).
- 测量包括T2D的临床标志物,和度 (视觉模拟尺度),外体miRNA表达和ex vivo炎症调节.
主要成果:
- 没有观察到对葡萄糖平衡 (葡萄糖,胰岛素,GLP-1) 的显著影响.
- 八种外体miRNA被CCB显著改变,其中三种 (miR-20A-5p,miR-23A-3p,miR-17-5p) 与改善的胰岛素敏感性有关.
- 摄入CCB减少了饥饿感,治疗A显著降低了超重个体的早期葡萄糖增加.
结论:
- 可可-胡卜混合物 (CCB) 的急性摄入在2型糖尿病 (T2D) 患者中显示出适度但显著的影响.
- 观察到的外体miRNAs的变化和减少饥饿感表明对代谢健康的潜在益处.
- 需要长期随机对照试验来验证这些初步发现.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126
MicroRNAs
2.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
2.9K
Carbohydrate Metabolism
10.6K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.6K
Dipeptidyl Peptidase 4 Inhibitors
139
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
139


